Multiple endocrine neoplasia type 2 future or investigational therapies: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
==Future or investigational therapies== | ==Future or investigational therapies== | ||
Further studies on the molecular pathways of c-RET gene and its protein will help to design novel and more individualized therapeutic modalities based on genetic information. In fact, although the knowledge about mechanisms of tumor development in patients with MEN2 has grown tremendously, much work lies ahead. The final goal is to offer patients with c-RET germline mutations an optimal cancer prevention and treatment program. | Further studies on the molecular pathways of c-RET gene and its protein will help to design novel and more individualized therapeutic modalities based on genetic information. In fact, although the knowledge about mechanisms of tumor development in patients with MEN2 has grown tremendously, much work lies ahead. The final goal is to offer patients with c-RET germline mutations an optimal cancer prevention and treatment program. | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | |||
|+'''''Ongoing trials''''' | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|Drug}} | |||
! style="background: #4479BA; width: 550px;" | {{fontcolor|#FFF|Target molecule}} | |||
|- | |||
! style="background: #F5F5F5;" | Axitinib | |||
922 | |||
! style="background: #F5F5F5;" | VEGFR, PDGFR beta, C. Kit | |||
|- | |||
! style="background: #F5F5F5;" | Gefitinib | |||
mutations | |||
! style="background: #F5F5F5;" | EGFR | |||
|- | |||
! style="background: #F5F5F5;" | Imatinib | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, BCR-ABL | |||
|- | |||
! style="background: #F5F5F5;" | Motesanib | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, PDGFR beta, C. Kit | |||
|- | |||
! style="background: #F5F5F5;" | Sorafenib | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, RET/PTC, BRAF, PDGFR beta, C. Kit | |||
|- | |||
! style="background: #F5F5F5;" | Sunitinib | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, RET/PTC, PDGFR beta | |||
|- | |||
! style="background: #F5F5F5;" | Vandetanib | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, RET/PTC, EGFR | |||
|- | |||
! style="background: #F5F5F5;" | XL184 | |||
and 891 mutations | |||
! style="background: #F5F5F5;" | VEGFR, RET, PDGFR beta | |||
|- | |||
| style="padding: 5px 5px; background: #F5F5F5;" colspan="2"|<small>Adapted from C. Romei, E. Pardi, F. Cetani, and R. Elisei Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2, Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036 </small> | |||
|} | |||
|} | |||
==Reference== | ==Reference== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 20:07, 26 September 2015
|
Multiple endocrine neoplasia type 2 Microchapters |
|
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Multiple endocrine neoplasia type 2 future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 future or investigational therapies |
|
FDA on Multiple endocrine neoplasia type 2 future or investigational therapies |
|
CDC on Multiple endocrine neoplasia type 2 future or investigational therapies |
|
Multiple endocrine neoplasia type 2 future or investigational therapies in the news |
|
Blogs on Multiple endocrine neoplasia type 2 future or investigational therapies |
|
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Future or investigational therapies
Further studies on the molecular pathways of c-RET gene and its protein will help to design novel and more individualized therapeutic modalities based on genetic information. In fact, although the knowledge about mechanisms of tumor development in patients with MEN2 has grown tremendously, much work lies ahead. The final goal is to offer patients with c-RET germline mutations an optimal cancer prevention and treatment program.
| Drug | Target molecule |
|---|---|
| Axitinib
922 |
VEGFR, PDGFR beta, C. Kit |
| Gefitinib
mutations |
EGFR |
| Imatinib
and 891 mutations |
VEGFR, RET, BCR-ABL |
| Motesanib
and 891 mutations |
VEGFR, RET, PDGFR beta, C. Kit |
| Sorafenib
and 891 mutations |
VEGFR, RET, RET/PTC, BRAF, PDGFR beta, C. Kit |
| Sunitinib
and 891 mutations |
VEGFR, RET, RET/PTC, PDGFR beta |
| Vandetanib
and 891 mutations |
VEGFR, RET, RET/PTC, EGFR |
| XL184
and 891 mutations |
VEGFR, RET, PDGFR beta |
| Adapted from C. Romei, E. Pardi, F. Cetani, and R. Elisei Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2, Journal of Oncology, vol. 2012, Article ID 705036, 15 pages, 2012. doi:10.1155/2012/705036 | |
|}